



ABOUT

John Sagartz, DVM, Ph.D., DACVP Chief Strategy Officer and Director

~25 Years of Experience

Areas of Expertise

- Toxicologic Pathology
- Drug Development
- Animal Models of Disease
- Management
- Strategy Development
- Biologics

John Sagartz has been the chief strategy officer at Inotiv since November 2018, working to help define and accelerate plans for the company's growth. Dr. Sagartz founded and led Seventh Wave Laboratories for over 15 years, prior to Inotiv's legacy company, BASi, acquiring Seventh Wave's operations in July of 2018. Following the acquisition, he joined Inotiv's board of directors to help guide operations to provide broader solutions and greater scientific expertise to the company's clients.

Dr. Sagartz began his career as a toxicologic pathologist at Searle/Monsanto in 1996. There, he held positions of increasing responsibility as section head, director, preclinical development site head, and fellow, following Monsanto's merger with Pharmacia. After Pfizer's acquisition of Pharmacia in 2003, John served Seventh Wave as president and chief executive officer, and chief strategy officer. He received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Kansas State University and, after completing residency training in anatomic pathology, earned his Doctor of Philosophy from The Ohio State University.

